Preferred Name | Daunorubicin | |
Synonyms |
DAUNORUBICIN Daunorrubicina daunorubicin Rubomycin C 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)- Rubidomycin L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha- RUBOMYCIN C Daunorubicin Leukaemomycin C (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione DAUNOMYCIN DNR Daunomycin daunomycin |
|
Definitions |
An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C62091 |
|
ALT_DEFINITION |
The active ingredient in a drug used to treat acute leukemias and some other types of cancer. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. It is a type of anthracycline antibiotic and a type of topoisomerase inhibitor. |
|
CAS_Registry |
20830-81-3 |
|
CHEBI_ID |
CHEBI:41977 |
|
Chemical_Formula |
C27H29NO10 |
|
code |
C62091 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173234 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C174019 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
Contributing_Source |
CTRP FDA GDC HemOnc PCDC |
|
DEFINITION |
An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. |
|
Display_Name |
Daunorubicin |
|
FDA_UNII_Code |
ZS7284E0ZP |
|
FULL_SYN |
DAUNORUBICIN Daunorrubicina daunorubicin Rubomycin C 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)- Rubidomycin L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha- RUBOMYCIN C Daunorubicin Leukaemomycin C (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione DAUNOMYCIN DNR Daunomycin daunomycin |
|
Has_Salt_Form | ||
Has_Target | ||
Is_PCDC_AML_Authorized_Value_For_Variable | ||
Is_Value_For_GDC_Property | ||
label |
Daunorubicin |
|
Legacy Concept Name |
Daunorubicin |
|
Maps_To |
Daunorubicin |
|
Preferred_Name |
Daunorubicin |
|
prefixIRI |
Thesaurus:C62091 |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C0011015 |
|
subClassOf |